Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lidocaine hydrochloride + bacitracin zinc + polymyxin b sulfate + neomycin sulfate is an OTC topical combination product that pairs three first-aid antibiotics with a local anesthetic for minor wound care. Bacitracin zinc inhibits bacterial cell-wall synthesis, polymyxin B disrupts the outer membrane of susceptible Gram-negative bacteria, neomycin is an aminoglycoside that inhibits bacterial protein synthesis, and lidocaine blocks voltage-gated sodium channels to provide temporary local analgesia. Publicly verifiable marketed products include **Neosporin Plus Lidocaine** from Kenvue and generic **Triple Antibiotic Plus Lidocaine** ointments from companies such as Trifecta Pharmaceuticals USA and Shandong Teking Pharmaceutical. The labeled use is prevention of infection and temporary relief of pain or discomfort in minor cuts, scrapes, and burns; the provided painful urethritis context appears to reflect confusion with lidocaine hydrochloride jelly rather than this four-ingredient skin ointment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine hydrochloride + bacitracin zinc + polymyxin b sulfate + neomycin sulfate.